ROIV Roivant Sciences Ltd.
2026Q1 · CUSIP G76279101 · Sector: Healthcare & Biotech
Lit · Institutions accelerating in
Holders
436
Δ holders QoQ
+42
Breadth percentile
Top 6%
Whale holders
181
Δ whales
+11
Inst. holding value
$14.6B
New positions
92
Closed positions
50
Price momentum (1Q)
—
Put / Call
12/10
Breadth history (34 quarters)
Past Lit Events & Aftermath 13 lit events
| Period | Percentile | Next-1Q return | Next-2Q return |
|---|---|---|---|
| 2026Q1 | Top 6% | — | — |
| 2025Q4 | Top 8% | — | — |
| 2025Q2 | Top 12% | — | — |
| 2024Q4 | Top 19% | — | — |
| 2024Q2 | Top 5% | — | — |
| 2024Q1 | Top 8% | — | — |
| 2023Q3 | Top 8% | — | — |
| 2023Q2 | Top 5% | — | — |
Options Sentiment
Put holders
12
QoQ: +2
Call holders
10
QoQ: -3
See methodology →
Fundamentals
PE (TTM)
—
EPS (TTM)
$-0.54
EPS YoY
—
Revenue (TTM)
$0.0B
Revenue YoY
-71.6%
Net margin
—
ROE
-6.6%
Debt ratio
7.3%
FCF (TTM)
-$759M
Dividend (TTM)
No dividend
Quarterly Revenue & EPS (4Y)
Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable
P/E (TTM) over time
P/E = close 47 days after quarter-end (filing date) ÷ TTM EPS then; loss quarters hidden
As of 2026-03-31 · SEC filings (XBRL)
Get the next update
2026Q2 holdings publish around Aug 15 — subscribe to receive the lists first.